Neoplasia/BPH

	A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. Eur Urol Chapin BF, Smaldone M, Zurita AJ, Wang J, Cooperberg MR, Gleave M, Delacroix SE, Davis J, Pettaway C, Pisters L, Adibi M, Chery L, Papadopoulos J, Ward J, Gregg J, Navai N, Corn P, Subudhi SK, Logothetis C, Kuban D, Nguyen Q, Tang C, Choi S, Hoffman K, Lozano M, Elsheftawi M, Achim M, Zhao Y, Ramesh N, Sei E, Navin N, Nogueras Gonzalez GM, Wang X, Zhu K, Troncoso P, Zhang M, McGuire S, Aparicio AM. PMID: 41833492 [PubMed - as supplied by publisher]
	Factors Associated With Testicular Cancer Risk Among New American Military Recruits During Wartime. Am J Mens Health Nelson DA, Hill OT, Skaggs SA, Brown WJ. PMID: 41833285 [PubMed - indexed for MEDLINE]
	Study of bladder cancer detection in standard white light versus AI-supported endoscopy-01 (RAISE-01) - Development and validation of an AI-based support tool. Int J Med Inform Hjort PB, Jensen JE, Jensen JB, Ernst A. PMID: 41833082 [PubMed - as supplied by publisher]
	A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP-00). Prostate King LD, Christie D, Cehic D, Dare W, Chess-Williams R, Sellers D, McDermott C, McCarthy A, Anoopkumar-Dukie S. PMID: 41833070 [PubMed - as supplied by publisher]
	Preferences of healthcare providers regarding future follow-up care for breast, prostate, and colorectal cancer: A discrete choice experiment. Support Care Cancer Liemburg GB, Stegmann ME, Burgers JS, Berendsen AJ, Berger MY, Schröder CP, Korevaar JC, Brandenbarg D. PMID: 41832396 [PubMed - indexed for MEDLINE]
	Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting. EJNMMI Res Harbi E, Bilgin GB, Emmett L, Kendi AT, Orme JJ, Muniz M, Childs DS, Lucien F, Chaudhuri AA, Sartor O. PMID: 41832388 [PubMed - as supplied by publisher]
	Genomic landscape and precision therapy in prostate cancer: current status and future directions. NPJ Precis Oncol Ligon JA, Anand S, Singh S, Siddiqui JA, Henegan JC, Singh AP. PMID: 41832316 [PubMed - as supplied by publisher]
	Predicting aggressiveness of clear cell renal cell carcinoma via mri using artificial intelligence: implications for surgical planning in a retrospective multicenter study. Sci Rep Zhao J, Wang H, Liao R, Liu M, Cui Z, Jin B, Wang Y, Tang R. PMID: 41832286 [PubMed - as supplied by publisher]
	Refining prognostication in non-muscle-invasive bladder cancer: From clinical models to artificial intelligence. Urol Oncol Mardelli C, Bertail T, Tachibana I, Verhoest G, Mathieu R, Pradere B, Xylinas E, Roupret M, Margulis V, Bensalah K, Lotan Y, Khene ZE. PMID: 41832109 [PubMed - as supplied by publisher]
	A Practical Phenotyping Framework for Male LUTS Using Remote Multi-Day Urinary Diagnostics. Urology Watts J, Godelfer D, Knoedler J, Sturdy A, Kaplan S, Sobol I. PMID: 41831697 [PubMed - as supplied by publisher]
	Clinical utility of large language models in metastatic prostate cancer: A multicenter expert validation for decision support. Eur J Cancer Chen Y, He K, Qu W, Ma L, Su X, Liu X, Kang Z, Li F, Yan J, Wang Z, Li J, Li Z. PMID: 41831267 [PubMed - as supplied by publisher]
	Role of molecular testing in diagnosis of renal neoplasms. Semin Diagn Pathol Gilpatrick T, Sanchez NG, Greenland NY, Sirohi D. PMID: 41831250 [PubMed - as supplied by publisher]
	The prevalence and predictors of previous prostate cancer screening among men attending primary healthcare centers in Riyadh, Saudi Arabia. Ann Med Alshahrani S, Shubair MM, Alfallaj AA, Al-Khateeb BF, Alshahrani A, Almutairi N, Alnaim L, Angawi K, Alharthy A, Othman F, El-Metwally A. PMID: 41830420 [PubMed - indexed for MEDLINE]
	ERG expression in BPH vs prostatic adenocarcinoma and its correlation with Gleason grade group. J Pak Med Assoc Qayyum M, Shawana S, Nomani BH, Khaliq E, Jamal N, Qayyum H. PMID: 41830348 [PubMed - indexed for MEDLINE]
	Efficacy and Safety of Vibegron Add-On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With Î±(1)-Blocker Treatment: A Multi-Center Prospective Randomized Controlled Study (VATON Study). Low Urin Tract Symptoms Yoshida M, Nishino Y, Nagae H, Kato S, Sakamoto S, Hojo M, Miyauchi T, Kageyama S, Takahashi S, Kuroda H, Mori N, Kasagi Y, Masunaga K, Nabeshima Y, Nomiya M, Iwashita K, Miyamae K, Otani M, Kawahara K, Ikeda M, Kubono S, Haga N. PMID: 41830191 [PubMed - indexed for MEDLINE]
	Serum Chemokines CCL3 and CCL7 as Complementary Diagnostic Biomarkers Across Tumor Grades in Clear Cell Renal Cell Carcinoma. Int J Mol Sci Sokólska W, Zajkowska M, Kulczy, Werel T, Orywal K. PMID: 41828706 [PubMed - indexed for MEDLINE]
	Impact of Heterogeneous DNA Methylation on the Accuracy of Quantitative Methylation-Specific PCR for Detecting DNA Hypermethylation in Prostate Cancer. Int J Mol Sci Visser WCH, de Jong H, Janssen LB, Shrivastava J, Mulders PFA, Schalken JA, Melchers WJG. PMID: 41828470 [PubMed - indexed for MEDLINE]
	Use of Artificial Intelligence Model Associated with Masson's Trichrome Staining as a Predictor of Muscle Invasion in Bladder Cancer. Int J Mol Sci Parrao D, Gallegos H, Ruz K, Lay R, Saavedra C, Guerrero R, Larrañaga M, Lindsay CB, Bravo JC. PMID: 41828460 [PubMed - indexed for MEDLINE]
	Updates on Clinical Trials and Molecular Characteristics of Locally Advanced and Oligometastatic Renal Cell Carcinoma. Int J Mol Sci Ogunmola TM, Jin Z, Kleberg J, Tithi TI, Anvar S, Maharjan CK, Chatzkel JA, Falzarano SM, Kolb R, Kim MC, Zhang W. PMID: 41828416 [PubMed - indexed for MEDLINE]
	Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate Cancer. Cancers (Basel) Rahbar K, Bögemann M, Papavasilis P, Halim A, Kidd M. PMID: 41827804 [PubMed]

Articles 1 - 20 / 186359

Page 1 of 9318



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy